Giammanco G, De Grandi V, Pignato S, Dolci C, Congia M, Pisu C, De Virgiliis S
Istituto di Igiene e Medicina Preventiva, Università di Catania, Italy.
Postgrad Med J. 1987;63 Suppl 2:151-4.
Preliminary results of a trial involving a yeast-derived hepatitis B vaccine administered to 41 transfusion-dependent thalassaemic patients and 2 patients with spherocytosis are reported. Twenty-microgram doses of HBsAg were administered according to either a 0, 1, and 6 month or 0, 1, and 2 month schedule. Serum specimens collected prior to vaccination, one month after each vaccine dose, and again at 5 and 15 months, were tested for HBV markers and ALT. To date, seroconversion (anti-HBs titres greater than 10 IU/l) was observed in 15%, 67%, and 86% of patients one month following the three vaccine doses, respectively. Although the study is still in progress, a comparison of these results with those previously obtained using plasma-derived vaccine indicates that seroconversion to the recombinant yeast-derived vaccine is at least as high as that obtained by plasma-derived vaccines in patients affected by thalassaemia major.
报告了一项针对41名依赖输血的地中海贫血患者和2名球形红细胞增多症患者接种酵母源性乙肝疫苗试验的初步结果。按照0、1和6个月或0、1和2个月的接种程序，给予20微克剂量的乙肝表面抗原（HBsAg）。在接种疫苗前、每次接种疫苗后1个月以及5个月和15个月时采集血清标本，检测乙肝病毒（HBV）标志物和谷丙转氨酶（ALT）。迄今为止，在接种三剂疫苗后1个月，分别有15%、67%和86%的患者出现血清转化（抗-HBs滴度大于10 IU/l）。尽管该研究仍在进行中，但将这些结果与先前使用血浆源性疫苗获得的结果进行比较表明，重型地中海贫血患者对重组酵母源性疫苗的血清转化率至少与血浆源性疫苗相同。
